A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Lay Description
This will be a long-term multi-center study to comprehensively study patients with primary liver cancer (PLC).
Category
- Cancers and Other Neoplasms
- IRB Number
- STUDY00000023
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- No
Eligibility
- Eligible Ages
- -
- Eligible Genders
- All
- Accepts Healthy Volunteers
Inclusion Criteria
Patients with histologically/ultrasound/imaging confirmed or suspicious lesions of HCC or CCA.
Patients with planned or a history of at least 1 dose of immunotherapy for HCC or CCA.
Ability of subject to understand and the willingness to sign a written informed consent document.
Age > 18 years old at date of study consent
Exclusion Criteria
Patients with known HIV infection as these patients may have abnormal test results which may confound the endpoints of this study
Study Design
Study Contact
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Principal Investigator
Sukeshi Arora